Lantern Pharma Net Worth
Lantern Pharma Net Worth Breakdown | LTRN |
Lantern Pharma Net Worth Analysis
Lantern Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lantern Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lantern Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lantern Pharma's net worth analysis. One common approach is to calculate Lantern Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lantern Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lantern Pharma's net worth. This approach calculates the present value of Lantern Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lantern Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lantern Pharma's net worth. This involves comparing Lantern Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lantern Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Lantern Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lantern Pharma's net worth research are outlined below:
| Lantern Pharma generated a negative expected return over the last 90 days | |
| Lantern Pharma has high historical volatility and very poor performance | |
| Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lantern Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: LTRN Stock Earnings Lantern Pharma Misses EPS for Q1 2024 - MSN |
Lantern Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lantern Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lantern Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Lantern Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lantern Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lantern Pharma backward and forwards among themselves. Lantern Pharma's institutional investor refers to the entity that pools money to purchase Lantern Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perigon Wealth Management, Llc | 2024-09-30 | 28.9 K | Sigma Planning Corp | 2024-09-30 | 28.6 K | Horizon Asset Management Inc/ny | 2024-09-30 | 27.6 K | Bank Of New York Mellon Corp | 2024-06-30 | 26.5 K | Ubs Group Ag | 2024-06-30 | 25.5 K | State Street Corp | 2024-06-30 | 23.7 K | Tocqueville Asset Management L.p. | 2024-09-30 | 17 K | Meridian Wealth Management, Llc | 2024-06-30 | 14.9 K | Northern Trust Corp | 2024-09-30 | 12.8 K | Vanguard Group Inc | 2024-09-30 | 363.7 K | Cm Management, Llc | 2024-09-30 | 185 K |
Follow Lantern Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.76 M.Market Cap |
|
Project Lantern Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.44) | (0.41) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.39) | (0.37) |
When accessing Lantern Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lantern Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lantern Pharma's profitability and make more informed investment decisions.
Evaluate Lantern Pharma's management efficiency
Lantern Pharma has return on total asset (ROA) of (0.2807) % which means that it has lost $0.2807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4482) %, meaning that it created substantial loss on money invested by shareholders. Lantern Pharma's management efficiency ratios could be used to measure how well Lantern Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Lantern Pharma's Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Non Currrent Assets Other is likely to grow to about 47.8 K, while Total Assets are likely to drop about 36.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.77 | 2.50 | |
| Tangible Book Value Per Share | 3.77 | 2.50 | |
| Enterprise Value Over EBITDA | (1.56) | (1.64) | |
| Price Book Value Ratio | 1.13 | 1.19 | |
| Enterprise Value Multiple | (1.56) | (1.64) | |
| Price Fair Value | 1.13 | 1.19 | |
| Enterprise Value | 24.7 M | 23.5 M |
The strategic initiatives led by Lantern Pharma's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (0.45) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lantern Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lantern Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lantern Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lantern Pharma Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 26th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify | |
| 3rd of May 2024 Other Reports | ViewVerify |
Lantern Pharma Earnings per Share Projection vs Actual
Lantern Pharma Corporate Management
| DVM MS | CoFounder Advisor | Profile | |
| Nicole Leber | Finance Associate | Profile | |
| MS BS | Head Operations | Profile | |
| Kishor Bhatia | Chief Consultant | Profile | |
| Marc MD | Chief Therapeutics | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.